Questions From the Clinic on the Management of HR-Positive, HER2-Negative Early Breast Cancer: A Quickfire Countdown +++++++++

Expert Interview: Best Practices for AL Amyloidosis Management in the Community CME Expert Interview: Best Practices for AL Amyloidosis Management in the Community Authors: Shahzad Raza, MD, FACP https://www.medscape.org/viewarticle/expert-interview-best-practices-al-amyloidosis-management-2025a10002fg?page=1 Clinical Case Scenarios in HR-Positive, HER2-Negative Early Breast Cancer: Assess the Risk of Recurrence and Eligibility for Adjuvant Therapy CME Clinical Case Scenarios in HR-Positive, HER2-Negative Early Breast Cancer: Assess the Risk of Recurrence and Eligibility for Adjuvant Therapy Authors: Seth Wander, MD, PhD; Manali Bhave, MD https://www.medscape.org/viewarticle/1002194?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Which Patients With HR+/HER2- EBC Benefit From Intensification of Therapy? Expert Recommendations for Clinical Assessment CME Which Patients With HR+/HER2- EBC Benefit From Intensification of Therapy? Expert Recommendations for Clinical Assessment Authors: Joyce A. O’Shaughnessy, MD https://www.medscape.org/viewarticle/which-patients-hr-her2-ebc-benefit-intensification-therapy-2025a10002qz?page=1 Navigating New Horizons in PNH and ITP: Perspectives for the Community CME Navigating New Horizons in PNH and ITP: Perspectives for the Community Authors: Sandra E. Kurtin, PhD, ANP-C, AOCN, FAPO; Cindy Neunert, MD, MSCS; Srikanth Nagalla, MD, MS https://www.medscape.org/viewarticle/navigating-new-horizons-pnh-and-itp-perspectives-community-2025a10004g2?page=1 The Rise of Protein Degraders for Hematologic Malignancies: Exploring the Latest Data From ASH 2024 CME The Rise of Protein Degraders for Hematologic Malignancies: Exploring the Latest Data From ASH 2024 Authors: Sagar Lonial, MD, FACP; Constatine Tam, MBBS, MD, FRACP, FRCPath; Julio Chavez, MD, MS https://www.medscape.org/viewarticle/1002295?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Managing Adverse Events of Oral Adjuvant Therapies in Patients With HR+/HER2- Early Breast Cancer CME Managing Adverse Events of Oral Adjuvant Therapies in Patients With HR+/HER2- Early Breast Cancer Authors: Joyce A. O’Shaughnessy, MD https://www.medscape.org/viewarticle/managing-adverse-events-oral-adjuvant-therapies-patients-hr-2025a1000563?page=1 Sharing Expert Minds in Lung Cancer and Lung Neuroendocrine Tumors Delivering Optimal Patient Care CME Sharing Expert Minds in Lung Cancer and Lung Neuroendocrine Tumors Delivering Optimal Patient Care Authors: Martin Reck, MD, PhD; Catherine Bouvier; Melanie Lucas; Abdul Masoor, MBChB, PhD, MRCP; Marianne Pavel, MD https://www.medscape.org/viewarticle/1002284?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu Questions From the Clinic on the Management of HR-Positive, HER2-Negative Early Breast Cancer: A Quickfire Countdown CME Questions From the Clinic on the Management of HR-Positive, HER2-Negative Early Breast Cancer: A Quickfire Countdown Authors: Kevin Kalinsky, MD; Giuseppe Curigliano, MD, PhD https://www.medscape.org/viewarticle/1002378?sso=true&uac=148436CN&src=mkmcmr_driv_invit_mscpedu AL Amyloidosis in Focus: Ongoing Innovations and Applicability to Practice CME AL Amyloidosis in Focus: Ongoing Innovations and Applicability to Practice Authors: Kevin M. Alexander, MD; Vaishali Sanchorawala, MD; Pedro Vianna, MD; Shahzad Raza, MD, FACP https://www.medscape.org/viewarticle/al-amyloidosis-focus-ongoing-innovations-and-applicability-2025a100078z?page=1